Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Valvular heart disease (VHD) is the next epidemic in the cardiovascular field, affecting millions of people worldwide and having a major impact on health care systems. With aging of the population, the incidence and prevalence of VHD will continue to increase. However, VHD has not received the attention it deserves from both the public and policymakers. Despite important advances in the pathophysiology, natural history, management, and treatment of VHD including the development of transcatheter therapies, VHD remains underdiagnosed, identified late, and often undertreated with inequality in access to care and treatment options, and there is no medication that can prevent disease progression. The present review article discusses these gaps in the management of VHD and potential actions to undertake to improve the outcome of patients with VHD. © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Citation

David Messika-Zeitoun, Helmut Baumgartner, Ian G Burwash, Alec Vahanian, Jeroen Bax, Philippe Pibarot, Vince Chan, Martin Leon, Maurice Enriquez-Sarano, Thierry Mesana, Bernard Iung. Unmet needs in valvular heart disease. European heart journal. 2023 Jun 01;44(21):1862-1873

Expand section icon Mesh Tags


PMID: 36924203

View Full Text